Lupin New Jersey subsidiary gets thirteen observations

1 Apr 2022 , 10:58 AM

The facility underwent a USFDA inspection from 7 March 2022 to 30 March 2022.

Lupin assured of addressing these observations and said it will work closely with the agency to address their concerns. Furthermore, the company said that observations will not have an impact on disruption of supplies or the existing revenues from operations. The facility contributes less than 5% of the companys global revenues.

The drug maker assured to be compliant with good manufacturing practice standards across all its facilities.

Lupin is a transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The companys consolidated net profit jumped 24.47% to Rs 545.52 crore on a 3.57% rise in total revenue from operations to Rs 4160.93 crore in Q3 FY22 over Q3 FY21.

Shares of Lupin were trading 1.36% higher to Rs 756.20 on BSE.

Powered by Capital Market – Live News